Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults-Reference-Cited by-同舟云学术

Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults

Published:2019-04-02 Issue:4 Volume:114 Page:363-373
ISSN:0042-9007
Container-title:Vox Sanguinis
language:en
Short-container-title:Vox Sang

Author:

Lim Wendy¹^ORCID,Afif Waqqas²,Knowles Sandra³,Lim Gloria⁴,Lin Yulia⁵^ORCID,Mothersill Charmaine⁴,Nistor Irina⁶⁷,Rehman Faisal⁸,Song Christine⁹,Xenodemetropoulos Ted¹⁰

Affiliation:

1. Department of Medicine Division of Hematology and Thromboembolism St. Joseph's Healthcare Hamilton McMaster University Hamilton ON Canada

2. Department of Medicine Division of Gastroenterology and Hepatology Montreal General Hospital McGill University Montreal QC Canada

3. Department of Pharmacy Division of Clinical Pharmacology and Toxicology Sunnybrook Health Sciences Centre Toronto ON Canada

4. Department of Medicine Division of Hematology and Oncology St. Michael's Hospital University of Toronto Toronto ON Canada

5. Department of Laboratory Medicine and Molecular Diagnostics Division of Clinical Pathology Sunnybrook Health Sciences Centre Department of Laboratory Medicine and Pathobiology University of Toronto Toronto ON Canada

6. Department of Gastroenterology and Hepatology Halton Healthcare Services Oakville ON Canada

7. Queen's University Kingston ON Canada

8. Department of Medicine Division of Nephrology University Hospital London Health Sciences Centre Western University London ON Canada

9. Department of Medicine Division of Allergy and Immunology St. Michael's Hospital University of Toronto Toronto ON Canada

10. Department of Medicine Division of Gastroenterology McMaster University Medical Centre McMaster University Hamilton ON Canada

Funder

Pfizer Canada

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/vox.12773

Reference46 articles.

1. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management

2. The safety of available treatment options for iron-deficiency anemia

3. European Medicines Agency:Assessment report for: Iron containing intravenous (IV) medicinal products. EMEA/H/A‐31/1322. European Medicines Agency 2013[Last accessed: July 15 2018] Available from:http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/IV_iron_31/WC500150771.pdf.

4. Ferinject (Ferric Carboxymaltose):Summary of Product Characteristics. [Last accessed: January 17 2019] Available from:https://www.medicines.org.uk/emc/medicine/5910.

5. Injectafer (Ferric Carboxymaltose Injection):Full Prescribing Information. [Last accessed: January 17 2019] Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203565s000lbl.pdf.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maternal Fatigue after Postpartum Anemia Treatment with Intravenous Ferric Carboxymaltose vs. Intravenous Ferric Derisomaltose vs. Oral Ferrous Sulphate: A Randomized Controlled Trial;Journal of Clinical Medicine;2024-01-28

2. Intravenous Iron Therapy: Re-administration after Prior Adverse Reaction;Korean Journal of Family Medicine;2023-11-20

3. Brand ferumoxytol vs. generic ferumoxytol comparison across two dosing regimens: a cardiac MRI image quality study;Pediatric Radiology;2023-10-14

4. Acute aortic intraluminal thrombus with embolisation and lower-limb ischaemia following intravenous iron sucrose infusion reaction;BMJ Case Reports;2023-09

5. Guide to use of ferumoxytol for hepatic vascular assessment as part of dual contrast MRI;Pediatric Radiology;2023-08-21